| 前收盘价格 | 28.21 |
| 收盘价格 | 29.60 |
| 成交量 | 16,739,845 |
| 平均成交量 (3个月) | 5,700,627 |
| 市值 | 23,311,554,560 |
| 价格/销量 (P/S) | 1.46 |
| 股市价格/股市净资产 (P/B) | 4.73 |
| 52周波幅 |
| 营业利益率 (TTM) | -4,823.84% |
| 稀释每股收益 (EPS TTM) | -0.750 |
| 季度收入增长率 (YOY) | -16.10% |
| 季度盈利增长率 (YOY) | -96.70% |
| 总债务/股东权益 (D/E MRQ) | 1.93% |
| 流动比率 (MRQ) | 33.47 |
| 营业现金流 (OCF TTM) | -839.45 M |
| 杠杆自由现金流 (LFCF TTM) | -375.20 M |
| 资产报酬率 (ROA TTM) | -10.73% |
| 股东权益报酬率 (ROE TTM) | -12.54% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Roivant Sciences Ltd. | 看涨 | 看涨 |
AIStockmoo 评分
1.9
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.88 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Core |
| 内部持股比例 | 30.31% |
| 机构持股比例 | 83.49% |
| 52周波幅 | ||
| 中 | 34.00 (4.91%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 34.00 (4.91%) | 购买 | 29.52 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合